The Global Insulin Infusion Pumps Market to Surge at a

New York, USA, Oct. 26, 2022 (GLOBE NEWSWIRE) — The Global Insulin Infusion Pumps Market to Surge at a Significant CAGR of 8.69% by 2027, Assesses DelveInsight

The insulin infusion pumps market is anticipated to prosper as a result of factors including rising sedentary lifestyles, an aging population base that is more susceptible to developing diabetes, and a growing emphasis on enhancing the safety and usability of insulin infusion pumps. These factors are also anticipated to contribute to the insulin infusion market’s appreciable revenue growth throughout the forecast period (2022–2027).

DelveInsight’s Insulin Infusion Pumps Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, insulin infusion pumps market drivers, barriers, and trends, and key insulin infusion pumps companies in the market.

Key Takeaways from the Insulin Infusion Pumps Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global insulin infusion pumps market during the forecast period.  
• Notable insulin infusion pumps companies such as F. Hoffmann-La Roche Ltd, Medtronic, Medtrum Technologies Inc., A. Menarini Diagnostic’s s.r.l., IA Collaborative Holdings, LLC, Apex Medical, Insulet Corporation, Ascensia Diabetes Care Holdings AG, Ypsomed AG, Tandem Diabetes Care, Inc., ICU Medical, Inc., SOOIL Developments Co., Ltd., MicroPort Scientific Corporation, Microtec Medical, and several others are currently operating in the insulin infusion pumps market.
• In September 2020, Medtronic received the U.S. Food and Drug Administration (FDA) clearance for its MiniMed 770G system, a new insulin pump system providing smartphone connectivity and an expanded age indication to ages 2 and above.
• In October 2019, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had expanded the label for Fiasp® (insulin aspart injection) to be included in…